- Report
- September 2021
- 111 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- April 2018
Global
From €4324EUR$4,500USD£3,712GBP
- Report
- October 2023
- 75 Pages
India
From €3219EUR$3,350USD£2,763GBP
- Report
- September 2022
- 76 Pages
Brazil
From €3219EUR$3,350USD£2,763GBP
- Report
- September 2022
- 77 Pages
France
From €3219EUR$3,350USD£2,763GBP
- Report
- September 2022
- 75 Pages
Germany
From €3219EUR$3,350USD£2,763GBP
- Report
- October 2019
- 128 Pages
Global
From €10564EUR$10,995USD£9,069GBP
- Report
- March 2021
- 52 Pages
Global
€1266EUR$1,318USD£1,087GBP
- Report
- September 2020
- 65 Pages
Global
€1266EUR$1,318USD£1,087GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- April 2023
- 113 Pages
Global
€3363EUR$3,500USD£2,887GBP
- Report
- August 2019
- 140 Pages
Global
From €3843EUR$4,000USD£3,299GBP
- Report
- April 2018
United States
From €7682EUR$7,995USD£6,595GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21139EUR$22,000USD£18,146GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21139EUR$22,000USD£18,146GBP
- Report
- May 2018
- 61 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- October 2023
- 112 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- June 2023
- 83 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- May 2023
- 102 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$3,902USD£3,110GBP
Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms.
Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections.
The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more